Live Webinar: Checkpoint, Claudin, and Beyond: Optimizing Biomarker-Driven Decisions in Advanced/Metastatic G/GEJ Cancer Care
Event Date
Wednesday,
November 12, 2025
Location
Virtual Live Event
Event Time
2:00pm Eastern
(11:00am Pacific)
Completion Time
60 minutes
Specialty
Gastroenterology, Hematology-Oncology, Primary Care
Topic(s)
Oncology, Pharmacology
This activity is provided by Prime.
Credit Available
- 1.0 CME/CE for Physicians (ACCME)
- 1.0 CME/CE for Physician Assistants (AAPA)
- 1.0 CH/CE for Nurse Practitioners (AANP)
- 1.0 CPE for Pharmacists (ACPE + NABP)
- 1.0 CNE for Nurses (ANCC)
All other healthcare professionals completing this course will be issued a statement of participation.
Program Overview
The treatment landscape for advanced gastric and gastroesophageal junction (G/GEJ) adenocarcinomas has evolved rapidly, with a surge of biomarkers, therapies, and clinical trial data reshaping standards of care. This dynamic, expert-led live webinar is designed to help you navigate these changes with confidence, bringing clarity to biomarker testing guidelines, biomarker-driven frontline therapy selection, and toxicity management.
Through gamified case challenges and live polling, you'll actively apply the latest evidence to practice and sharpen your decision-making skills to advance patient care.
Learning Objectives
- Assess current practice patterns, knowledge gaps, clinical barriers, and facilitators to the implementation of biomarker-driven care in advanced gastric and gastroesophageal junction (G/GEJ) adenocarcinoma
- Incorporate the latest biomarker testing guidelines (including PD-L1, MSI/MMR, CLDN18.2, and HER2) into clinical practice for patients with advanced G/GEJ adenocarcinomas
- Evaluate the latest clinical trial data and guideline recommendations supporting the use of immune checkpoint inhibitors and CLDN18.2-directed therapies in patients with G/GEJ adenocarcinomas
- Apply evidence-based strategies to select appropriate biomarker-driven therapies for patients with advanced G/GEJ adenocarcinoma
- Employ optimal approaches for monitoring and managing adverse events associated with immunotherapies and targeted therapies in patients with advanced G/GEJ adenocarcinomas
Faculty
Manish A Shah, MD, FASCO
Speaker
Jaffer A. Ajani, MD
Speaker
Carolyn Oxencis, PharmD, BCOP, FHOPA – Moderator
Alexandra Vazquez Salgado, PhD – Contributing Author
Stephanie Joyce, PA, MSPAS, MS, RD – Planner
Michele B Kaufman, PharmD, BCGP – Planner
Jason Welch, MD – Peer Review